Objective: The aim of this study was to evaluate the extent to which mild disruptions in ovarian function, indexed by changes in menstrual cycle length, may relate to cardiometabolic and psychological health in premenopausal women.
A lthough cardiovascular disease (CVD) risk increases during the menopausal transition, 1<12 the disease processes underlying the emergence of CVD during this period may begin premenopausally, as is suggested by studies documenting fatty streaks and clinically significant atherosclerotic lesions in young premenopausal women and adolescent girls. 13<16 To date, however, factors contributing to atherosclerotic disease development premenopausally that may explain variability in CVD postmenopausally are poorly understood. In this context, Kaplan and Manuck 17, 18 have proposed the Bprecocious acceleration[ hypothesis, suggesting that disruptions in ovarian function during the premenopausal period (even when mild) can promote atherosclerosis, leading to an accelerated course of disease and increased postmenopausal risk for CVD. This hypothesis is supported by studies in which women with apparent impairments in ovarian functionVmarked by anovulation, lower estrogen, and menstrual cycle irregularityVexhibited increased risk for CVD or more problematic CVD risk factor profiles.
19<25
Poorer psychological health has been associated with disruptions in ovarian function indexed by menstrual cycle characteristics. Findings drawn from three largely separate literatures show that (i) women with psychiatric disorders frequently experience menstrual cycle abnormalities, including increased irregularity and patterns of both shorter and longer cycle length 26<29 ; (ii) psychological stress, especially when extreme, can play an etiologic role in the cessation of menses 30<33 ; and (iii) risk for depressive symptoms increases during perimenopause, a time when menstrual cycles become less regular owing to reproductive aging. 34 Poorer psychological health has also been associated with risk for CVD. In particular, depression, including major and minor depressive disorders and depressive symptoms, has been shown to predict incident myocardial infarction, cardiac-specific, and allcause mortality. 35<40 With respect to the examination of cardiovascular risk factors, depression, especially among women, confers risk for the development of metabolic syndrome, 41<43 and negative psychological factors more broadly are correlated (although not always 41, 42 ) with the individual components of metabolic syndrome (ie, high-density lipoprotein [HDL] , triglycerides, waist circumference, glucose, and blood pressure).
43<45
To integrate and extend the existing literature, the primary goal of the current study was to evaluate whether mild disruptions in ovarian function among healthy, regularly cycling women are related to markers of cardiometabolic health and depression. Given the interrelations between disruptions in ovarian function, cardiometabolic risk factors, and depression, the secondary goal was to explore a model in which disruptions in ovarian function were proposed to play a mediating role (at least partially) in linking depression and cardiometabolic risk. The study objectives were pursued in a multiethnic sample of 804 healthy, regularly cycling premenopausal women in whom we examined disruptions in ovarian function, as marked by having experienced any change in menstrual cycle length (ie, shortening, lengthening, or increased variability) compared with no change in menstrual cycle length in relation to standard cardiometabolic risk factors and current depressive symptoms and depression history.
METHODS

Participants
The current sample included participants in the Ovarian Aging (OVA) Study, an investigation of the correlates of reproductive aging. Participants were recruited through Kaiser Permanente of Northern California, a large integrated healthcare delivery system that provides medical care to approximately one third of the population of Northern California. The Kaiser Permanente membership, compared with the population of Northern California, is generally representative in its sociodemographic and health-related characteristics, especially when the comparison is limited to those with health insurance. 46 Women were included in the OVA Study if they were between 25 and 45 years of age; had regular menses (ie, able to predict the start of menses within 5 d); had their uterus and both ovaries intact; self-identified as white, African American, Latina, Chinese, or Filipina; and were able to speak/read English, Spanish, or Cantonese. Exclusions included self-report of major medical illnesses, use of medications affecting the menstrual cycle in the 3 months before study enrollment, and current pregnancy or breast-feeding.
The OVA Study protocol included an in-person medical history interview, transvaginal ultrasound, anthropometric assessment, blood draw, and self-report questionnaires. Among 1,019 total participants, 804 women were included in the current analysis. Women (n = 215) were excluded because of the following: (1) menstrual cycle length outside the range of 25 to 35 days (n = 33); (2) use of a hormonal method of birth control in the past year (n = 25); (3) pattern of change not reflective of shortening, lengthening, or increased variability in menstrual cycle length (n = 127); or (4) missing information on a key variable related to reproductive history, cardiometabolic health, or reproductive aging (n = 30). In addition, a subset of 553 women with complete questionnaire data was included in analyses examining depression. Questionnaire data were missing for women who were never administered the questionnaires because the questionnaires were not initially included in the study protocol (n = 123) and for women who did not return the questionnaires (n = 128). The study protocol was approved by the University of California San Francisco Committee on Human Research and the Kaiser Permanente of Northern California Institutional Review Board. Informed, written consent was obtained from all study participants.
Measures
Menstrual cycle characteristics
In an in-person medical history interview, women were asked to report the number of days in their typical menstrual cycle during the past 12 months in categories: 25-27, 28-32, and 33-35 days. Women were also asked to report whether their typical menstrual cycle in the past 12 months reflected no change in length or had become shorter, longer, or more variable. In the current analyses, change in menstrual cycle length was coded as having experienced any change in menstrual cycle length (ie, shortening, lengthening, or increased variability) versus having experienced no change in menstrual cycle length.
Cardiometabolic risk factors
Cardiometabolic risk factors, including HDL, triglycerides, waist circumference, glucose, and hypertensive status, were assessed. Assays for HDL, triglycerides, and fasting glucose were performed by Quest Diagnostics (San Jose, CA). Lipids were assayed using enzymatic methods, and fasting glucose was assayed with the glucose oxidase method. Waist circumference, taken as the average of two measurements, was derived from a standardized anthropometric assessment performed by a study nurse. Lastly, previously diagnosed hypertension (yes/no) and use of antihypertensive medications (yes/no) were derived from an in-person medical history interview; endorsement of one or both items was used as a surrogate for measured systolic/diastolic blood pressure, which was not assessed in the study protocol. A cardiometabolic risk composite score was derived for use in the current analyses by taking the mean of the standardized values of each of the five individual cardiometabolic risk factors (with HDL reversed). Computation of a continuously measured cardiometabolic risk composite is consistent with several previous investigations.
Depressive symptoms and treatment history
Depressive symptoms were measured using the Center for Epidemiological Studies Depression Scale (CES-D). 52, 53 The CES-D is a 20-item, self-report questionnaire that assesses depressive symptoms during the past week. Each item is scored on a 0-3 point scale. Response choices indicate the frequency with which each symptom (or item) is experienced, ranging from Brarely or none of the time (G1 d)[ scored 0 to Bmost or all of the time (5-7 d)[ scored 3. After the reversal of scores on four positively worded questions, items are summed to produce a total score (range, 0-60), with higher values reflecting more depressive symptoms. A total score of 16 or higher is a commonly used cutoff owing to its correspondence with clinically significant levels of depression. 53, 54 The CES-D is a well-established instrument with adequate reliability 55, 56 and validity. 53 ,56<60 History of depression diagnosis and treatment were assessed using a standardized set of questions asking women to report whether they had ever received a diagnosis of and/or treatment for depression from a medical professional and the type of treatment that was received. Derived from CES-D and depression diagnosis/treatment history questions, depression variables examined in the current analyses included the CES-D total score coded 16 or higher (1 = yes; 0 = no), having received a depression diagnosis (1 = yes; 0 = no), and having used antidepressant medications (1 = yes; 0 = no). In addition, a lifetime history of depression composite score was computed by coding ever having received a depression diagnosis or ever having used antidepressant medications (1 = yes; 0 = no).
Reproductive aging
Reproductive aging was indexed by concentrations of anti-Müllerian hormone (AMH), a biochemical marker of ovarian reserve. 61, 62 AMH, secreted by the granulosa cells of the preantral and small antral follicles of the human ovary, 63 plays a key regulatory role in folliculogenesis by inhibiting the initial recruitment of primordial follicles into the growing pool of follicles. 64, 65 Validity for the use of AMH as an indicator of reproductive aging stems from studies showing that AMH correlates with the number of primordial follicles 66 ; relates inversely to chronological age in adult women 61, 67 ; and predicts menopausal onset 68, 69 as well as ovarian response in treatments using assisted reproductive technologies. 70, 71 AMH is also stable within and across menstrual cycles 72<76 and is not affected by the use of oral contraceptives. 76, 77 AMH was assayed using two commercially available enzyme-linked immunosorbent assays from Beckman Coulter (Marseille, France), both of which use a two-site sandwich immunoassay. The Immunotech assay was used for the majority of the sample (84%) until it was retired, and a second-generation assay (Gen II) was used for the remainder of the sample. Among 44 women on whom both assays were performed, regression analyses showed excellent correspondence between the assays (R 2 = 0.94), which has also been demonstrated in prior studies. 78, 79 AMH values based on the Immunotech assay were adjusted using the equation of the line, with Immunotech predicting Gen II. The Gen II assay sensitivity was 0.16 ng/mL, the intraassay coefficient of variation was 1.4%, and the interassay coefficient of variation was 12.5%.
Statistical analyses
Logistic regression analyses were performed to evaluate cardiometabolic risk and depression in relation to the odds of being in one of two groups of women: either having experienced a change in menstrual cycle length (ie, shortening, lengthening, or increased variability during the past 12 mo) or having experienced no change in menstrual cycle length. First, a cardiometabolic risk composite score (representing five individual cardiometabolic risk factors [HDL, triglycerides, waist circumference, glucose, and hypertensive status], with HDL reversed) was examined in relation to group membership. Second, in separate models, four indicators of current depressive symptoms and treatment history (CES-D score Q16 [yes/no], depression diagnosis [yes/no], use of antidepressant medications [yes/no], and lifetime history of depression composite score [yes/no]) were examined in relation to group membership. Next, AMH was added to the models to determine whether associations between cardiometabolic risk/depression and group membership were independent of variability in reproductive aging. All models included covariate adjustment for age, race/ethnicity (represented by four dummy-coded variables, with white as referent), socioeconomic status (SES) indexed by individual-level education To explore a conceptual model of possible interrelations between disruptions in ovarian function, cardiometabolic risk factors, and depression, a series of regression analyses were then performed to evaluate whether change in menstrual cycle length might play a mediational role in linking depression to cardiometabolic risk. In these analyses, depression was represented by the lifetime history of depression composite score, and cardiometabolic risk was indexed by the cardiometabolic risk composite score. In accordance with Baron and Kenny, 81 conditions for testing for mediation were evaluated first by examining relations between (1) the lifetime history of depression composite score and change in menstrual cycle length (path A); (2) change in menstrual cycle length and the cardiometabolic risk composite score, controlling for the lifetime history of depression composite score (path B); and (3) the lifetime history of depression composite score and the cardiometabolic risk composite score (path C). In models in which conditions for testing for mediation were met (ie, paths A, B, and C were all statistically significant), mediation was then tested by reevaluating path C with additional covariate adjustment for change in menstrual cycle length. Attenuation in path C was interpreted to indicate that change in menstrual cycle length mediates the relation between the lifetime history of depression composite score and the cardiometabolic risk composite score. Linear regression was performed when continuously measured outcomes were assessed, and binary logistic regression was performed when dichotomously coded outcomes were assessed. All models included covariate adjustment for the same variables defined in detail above (age, race/ ethnicity, SES, smoking, physical activity level, parity, past use of a hormonal method of birth control, menstrual cycle length, and AMH).
RESULTS
Sample description
Eighty-one percent (n = 650) of the sample reported experiencing no change in menstrual cycle length, whereas patterns of shortening, lengthening, and increased variability were reported in 7% (n = 57), 5% (n = 38), and 7% (n = 59) of the sample, respectively. In Table 1 , descriptive information for the total sample is provided as well as statistical comparisons between women coded: any change in menstrual cycle length (ie, shortening, lengthening, or increased variability) and no change in menstrual cycle length. Women had a mean (SD) age of 35.3 (5.5) years, and the sample was ethnically diverse (29.7% white, 24% African American, 22.9% Latina, 19.3% Chinese, and 4.0% Filipina). Regarding the covariates, women who experienced any change in menstrual cycle length compared with no change in menstrual cycle length were more likely to report past use of a hormonal method of birth control (P G 0.01). Regarding the cardiometabolic risk variables, women who experienced any change in menstrual cycle length compared with no change in menstrual cycle length had higher cardiometabolic risk composite scores, had The lifetime history of depression composite score is coded having received a depression diagnosis or having used anti-depressant medications. lower HDL, and were more likely to have received a hypertensive diagnosis or to have used antihypertensive medication (P G 0.05). Lastly, regarding the depression variables, women who experienced any change in menstrual cycle length compared with no change in menstrual cycle length had higher CES-D scores (13.7 versus 10.7), were more likely to have a CES-D score of 16 or higher (P G 0.01), and were more likely to have received a depression diagnosis or to have used antidepressant medications (P G 0.001).
Are disruptions in ovarian function related to cardiometabolic risk? As reported in Table 2 , results of logistic regression analyses showed that with each one-unit increase in the cardiometabolic risk composite score (reflecting the mean of the standardized values of five individual cardiometabolic risk factors [HDL, triglycerides, waist circumference, glucose, and hypertensive status], with HDL reversed), the odds of experiencing any change in menstrual cycle length was increased by 43% (odds ratio [OR], 1.429; 95% CI, 1.063-1.920) compared with the odds of experiencing no change in menstrual cycle length. In addition, with each 1-SD increase in HDL, the odds of experiencing any change in menstrual cycle length was decreased by 24% (OR, 0.765; 95% CI, 0.628-0.933) compared with the odds of experiencing no change in menstrual cycle length. Greater waist circumference and hypertensive status were also associated with an increased odds of experiencing any change in menstrual cycle length compared with no change in menstrual cycle length, albeit at the level of a statistical trend (P G 0.10). Triglycerides and glucose were unrelated to categories of any change in menstrual cycle length compared with no change in menstrual cycle length (P 9 0.05). All results included adjustment for covariates, including age, race/ethnicity, SES, cigarette smoking, physical activity level, parity, past use of a hormonal method of birth control, and menstrual cycle length. When analyses were repeated with additional covariate adjustment for AMH, the pattern of results did not change (results not shown), suggesting that associations between cardiometabolic risk and change in menstrual cycle length were not attributable to variability in reproductive aging.
Are disruptions in ovarian function related to depression?
As reported in Table 3 , results of logistic regression analyses showed that having a CES-D score of 16 or higher, having received a depression diagnosis, and having used antidepressant medications were associated with a 2.1, 3.0, and 3.1 increased odds, respectively, of experiencing any change in menstrual cycle length compared with no change in menstrual cycle length. Examination of the lifetime history of depression composite score, reflecting endorsement of having received a depression diagnosis or having used antidepressant medications (1 = yes; 0 = no), was associated with a 2.6 increased odds of experiencing any change in menstrual cycle length compared with no change in menstrual cycle length. All results included adjustment for covariates, including age, race/ethnicity, SES, cigarette smoking, physical activity level, parity, past use of a hormonal method of birth control, and menstrual cycle length. When analyses were repeated with additional covariate adjustment for AMH, the pattern of results did not change (results not shown), suggesting that associations between indicators of depressive symptoms/ treatment history and change in menstrual cycle length were not attributable to variability in reproductive aging. Depression was represented by the lifetime history of depression composite score coded as having received a depression diagnosis or having used antidepressant medications (yes/no). Does ovarian function play a mediating role in linking depression to cardiometabolic risk? As reported in Table 4 , in covariate-adjusted analyses (controlling for age, race/ethnicity, SES, cigarette smoking, physical activity level, parity, past use of a hormonal method of birth control, menstrual cycle length, and AMH), conditions for testing for mediation were met. That is, regarding path A, the lifetime history of depression composite score was significantly related to change in menstrual cycle length (b = 0.990, P = 0.001; OR, 2.692; 95% CI, 1.507-4.808). Regarding path B, change in menstrual cycle length was significantly related to the cardiometabolic risk composite score (b = 0.125, P = 0.040), adjusted for the lifetime history of depression composite score. Regarding path C, the lifetime history of depression composite score was significantly related to the cardiometabolic risk composite score (b = 0.152, P = 0.040). When path C was reevaluated, including additional covariate adjustment for change in menstrual cycle length, the association between the depression composite score and the cardiometabolic risk composite score was attenuated (b = 0.129, P = 0.083), suggesting that change in menstrual cycle length partially mediates the relation between the lifetime history of depression composite score and the cardiometabolic risk composite score (Fig. 1) .
DISCUSSION
In cross-sectional analyses of 804 healthy, regularly cycling premenopausal women, results indicated that any change in menstrual cycle length in the previous 12 months versus no change was associated with increased cardiometabolic risk and depression. Associations were independent of statistical control for age, race/ethnicity, SES, cigarette smoking, physical activity level, parity, past use of a hormonal method of birth control, and menstrual cycle length. When AMH (a marker of ovarian reserve) was additionally covaried, results did not change, suggesting that variability in reproductive agingVat least in this relatively young (mean age, 35 y) premenopausal sample of womenVdoes not account for associations between changes in menstrual cycle length and cardiometabolic risk/depression. Lastly, results of exploratory analyses (albeit based on cross-sectional data) supported the proposed conceptual model suggesting that ovarian function may play a mechanistic role in linking depression to cardiometabolic risk, as demonstrated by results in which any change in menstrual cycle length compared with no change in menstrual cycle length partially mediated the relation between lifetime history of depression and the cardiometabolic risk composite score.
Each one-unit increase in the cardiometabolic risk composite score (reflecting the composite of five individual cardiometabolic risk factors, including HDL [reversed], triglycerides, waist circumference, glucose, and hypertensive status), was associated with a 43% increased odds of experiencing any change in menstrual cycle length compared with no change in menstrual cycle length. This finding is consistent with prior studies in which menstrual cycle irregularity has been shown to be an independent risk factor for CVD.
21<23, 25 However, irregularity has been defined inconsistently and commonly represents more extreme patterns (eg, very short [G21 d] or very long [Q40 d] cycles) that may reflect an underlying clinical condition such as polycystic ovarian syndrome. Other prior studies have also reported that a longer menstrual cycle length was associated with CVD risk factors, including higher body mass index and lower HDL, 19, 82, 83 although menstrual cycle length and not change in menstrual cycle length was examined in these studies. Thus, the current findings are unique in suggesting that more subtle changes in menstrual cycle length among healthy, regularly cycling women are also related to cardiometabolic risk and that change in menstrual cycle length, even independently of menstrual cycle length itself, may contribute to this risk.
Indicators of depressive symptoms and treatment history were associated with experiencing any change in menstrual cycle length compared with no change in menstrual cycle length. Associations were present across a range of depression indicators representing normative variability in depressive symptoms and more clinically significant outcomes. In particular, the lifetime history of depression composite score, reflecting having ever received a depression diagnosis or having ever used antidepressant medications, was associated with a 2.6-fold increase in the odds of experiencing any change in menstrual cycle length compared with no change in menstrual cycle length. Our findings are generally consistent with previous studies showing that women with psychiatric disorders disproportionately experience abnormalities in menstrual cycle characteristics, reflected by irregular cycles and patterns of both shorter and longer length. 26<29 However, as mentioned previously with respect to the examination of cardiometabolic risk, menstrual cycle length and not change in menstrual cycle length was examined in these studies.
FIG. 1.
Mediational model depicting attenuation in the association between depression history and cardiometabolic risk after adjustment for ovarian function. Depression history was represented by the lifetime history of depression composite score coded as having received a depression diagnosis or having used antidepressant medications (1 = yes; 0 = no). Ovarian function was indexed by changes in menstrual cycle length coded as any change (shorter, longer, or more variable) versus no change. Cardiometabolic risk was represented by the cardiometabolic risk composite score reflecting the mean of the standardized values of five individual risk factors (high-density lipoprotein, triglycerides, waist circumference, glucose, and hypertensive status).
All models were reevaluated, additionally including AMH as a covariate, to account for the possibility that self-reported changes in menstrual cycle length may reflect accelerated reproductive aging, which has itself been recently linked to depressive symptoms and psychological stress. 84, 85 In descriptive analyses, mean levels of AMH were lower among women reporting any change in menstrual cycle length compared with no change in menstrual cycle length, consistent with studies suggesting that menstrual cycles initially shorten with age. 86, 87 However, the inclusion of AMH in multivariate models did not account for associations between any change in menstrual cycle length compared with no change in menstrual cycle length and cardiometabolic risk/depression, indicating that reproductive aging did not make a significant contribution to the current model. It remains possible, however, that as the current sample ages and the number of women experiencing changes in menstrual cycle length increases, variability in reproductive aging may become a more prominent factor in explaining these changes.
The current study had several significant weaknesses, including that patterns of change in menstrual cycle length were self-reported and retrospective, with women reporting changes in a typical cycle during the past 12 months. Furthermore, depression indicators (having received a depression diagnosis and having used antidepressant medications) were derived from a self-report questionnaire and were not confirmed by other sources such as diagnostic psychiatric interviews or medical records. In addition, owing to the small number of women in each change category (ie, shortening, lengthening, or increased variability), we could not analyze these groups separately. Most notably, because the analyses were cross-sectional, the direction of association between the variables of interest cannot be determined. In particular, although we proposed (on an exploratory basis) a conceptual model suggesting that depression may negatively impact ovarian function and cardiometabolic risk (possibly via disruptions in ovarian function), it is plausible that associations are actually bidirectional. That is, depressive symptoms may also result from disruptions in ovarian function, and cardiometabolic risk factors may play a role in promoting depressive symptoms. 88, 89 A primary strength of the current study was its novel emphasis on examining disruptions in ovarian function among women who are healthy and regularly cycling. In addition, the sample itself was well-characterized for reproductive history, cardiometabolic risk factors, and potential confounding variables.
CONCLUSIONS
Overall, results provide indirect support for Kaplan and Manuck's 17, 18 Bprecocious acceleration[ hypothesis, which proposes that even mild disruptions in ovarian function premenopausally may promote atherosclerosis. In summary, findings from the current study suggest that subtle disruptions in ovarian function, marked by changes in menstrual cycle length, are observable even in healthy, regularly cycling women, and that these changes (compared with no change) are associated with increased cardiometabolic risk and depression. In addition, exploratory analyses suggest that changes in menstrual cycle length may partially mediate relations between depression and cardiometabolic risk, although this finding should be considered preliminary only owing to the cross-sectional nature of the data. Future longitudinal studies are needed to more fully examine the complex interrelations between reproductive, cardiometabolic, and psychological health in women and to delineate the mechanisms linking these areas.
